Chronic Hand Eczema

A survey by LEO Pharma indicates widespread misunderstandings about chronic hand eczema, revealing significant emotional and occupational challenges for patients.

The company also announced in a press release that the product received the Seal of Acceptance by the NEA.

Raj Chovatiya, MD, PhD, MSCI, discusses his approach to diagnosing and treating chronic hand eczema.

Patients reported the face, neck, and inner arms as the most affected body regions before treatment.

Hand eczema affects 22.4% of adults in East Greenland, with prevalence, severity, and risk factors mirroring trends other populations.

Gooderham continues a discussion on new data reinforcing the safety of topical delgocitinib, with minimal systemic absorption even under maximal use conditions.

At the 2025 AAD Annual Meeting, Gooderham shared data on the negligible systemic exposure of delgocitinib cream for chronic hand eczema.

Patients with CHE saw higher treatment success and a favorable safety profile with delgocitinib 20-30 mg/g.

Participants from the parent DELTA 1 and 2 studies maintained their disease control and observed a decrease in pain and itch over 52 weeks of treatment.

JiaDe Yu, MD, discussed important clinical issues in allergic contact dermatitis at the AAD Annual Meeting.

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.

A new survey reveals widespread misunderstanding and lack of effective treatments in chronic hand eczema.

DELTA China follows the success of European and Canadian trials, reinforcing delgocitinib’s potential as a global treatment for CHE.

The phase 3 clinical trial investigating delgocitinib cream for adolescents with moderate to severe CHE met its primary and key secondary endpoints.

His presentation at South Beach Symposium will feature Zirwas’ insights on JAK inhibitors, eczema treatments, and emerging therapies.

The drug, a JAK inhibitor, met all primary and secondary endpoints in a phase 3 trial for adolescent CHE.

Chronic hand eczema poses diagnostic and treatment challenges due to its multifaceted etiology. New therapies like JAK inhibitors offer hope.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in chronic hand eczema this year.

Catch up on exclusive interviews with Christopher Bunick, MD, PhD; Raj Chovatiya, MD, PhD; and Alexander Egeberg, MD, PhD, from quarter 4 dermatologic conferences.

The study found that those who worked with wet hands and had chapped skin had a higher severity of chronic hand eczema.

Treatment with delgocitinib led to a significant decrease in the expression of inflammatory markers that were elevated in severe cases compared with mild cases at baseline.

Learn more about the in-depth topics covered in the November 2024 CHE digital supplement of Dermatology Times.

Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.

Delgocitinib is indicated for adults with CHE who either do not respond to or cannot use topical corticosteroids.

Clinical trial exit interviews reveal detailed perspectives on disease burden for patients with chronic hand eczema.